{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:37:26Z","timestamp":1767109046176,"version":"build-2065373602"},"reference-count":28,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Humans infected with SARS-CoV-2 may develop COVID-19, which manifests across a wide spectrum of clinical severity ranging from mild upper respiratory tract illnesses to diffuse viral pneumonia, causing acute respiratory failure. Many therapies have been tested for their efficacy in treating COVID-19. Controversy surrounds convalescent plasma transfusions as an effective treatment for COVID-19. This study discusses the efficacy of this treatment on COVID-19 patients. Electronic medical record data were collected from patients diagnosed with COVID-19, from November 2020 to August 2021, in the Galilee Medical Center\u2019s COVID-19 departments. Epidemiological, clinical, laboratory and imaging variables were analyzed. Multivariate stepwise regression and discriminant analyses were used to identify and validate the correlation between convalescent treatment and either death or time to negative PCR and hospitalization length. The study population included 270 patients, 100 of them treated with convalescent plasma. The results show that convalescent plasma therapy significantly prevented mortality in moderate patients, reduced hospitalization length and time to negative PCR. Additionally, high BMI, elderly age, high CRP and 4C-scores correlated with the severity and mortality of COVID-19 patients. Convalescent plasma also significantly reduced inflammatory markers, especially in moderate COVID-19 patients. In non-critical hospitalized patients, convalescent plasma therapy reduces morbidity and mortality in moderate COVID-19 patients and hospitalization length. Identifying patients who could benefit from this treatment could reduce the risk of death and shorten their hospitalization stay.<\/jats:p>","DOI":"10.3390\/metabo11110761","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T10:33:09Z","timestamp":1636108389000},"page":"761","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Convalescent Plasma Reduces Mortality and Decreases Hospitalization Stay in Patients with Moderate COVID-19 Pneumonia"],"prefix":"10.3390","volume":"11","author":[{"given":"Maamoun","family":"Basheer","sequence":"first","affiliation":[{"name":"Internal Medicine Department, Galilee Medical Center, Nahariya 2210001, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Saad","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Galilee Medical Center, Nahariya 2210001, Israel"},{"name":"The Azrieli Faculty of Medicine, Bar-Ilan University, Safad 2210001, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorin","family":"Shlezinger","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Galilee Medical Center, Nahariya 2210001, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6041","authenticated-orcid":false,"given":"Nimer","family":"Assy","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Galilee Medical Center, Nahariya 2210001, Israel"},{"name":"The Azrieli Faculty of Medicine, Bar-Ilan University, Safad 2210001, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/all.14238","article-title":"Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China","volume":"75","author":"Zhang","year":"2020","journal-title":"Allergy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"HLH Across Speciality Collaboration, UK. COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"ref_6","unstructured":"World Health Organization (2020, March 30). Home Care for Patients with COVID-19 Presenting with Mild Symptoms and Management of Their Contacts. Available online: https:\/\/www.who.int\/publications-detail\/home-care-for-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts."},{"key":"ref_7","unstructured":"National Institutes of Health (2021, August 18). Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, Available online: https:\/\/covid19treatmentguidelines.nih.gov\/introduction\/."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.2020.4940","article-title":"Convalescent plasma to treat COVID-19: Possibilities and challenges","volume":"323","author":"Roback","year":"2020","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/jmv.25882","article-title":"Treatment with convalescent plasma for COVID-19 patients in Wuhan, China","volume":"92","author":"Ye","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.ajpath.2020.05.014","article-title":"Treatment of COVID-19 patients with convalescent plasma","volume":"190","author":"Salazar","year":"2020","journal-title":"Am. J. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.3324\/haematol.2020.261784","article-title":"Mortality reduction in 46 severe COVID-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial","volume":"105","author":"Perotti","year":"2020","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1038\/s41467-021-23469-2","article-title":"Convalescent Plasma for COVID-19. A Randomized Clinical Trial","volume":"12","author":"Gharbharan","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-020-1088-9","article-title":"Convalescent plasma treatment of severe COVID-19: A propensity score\u2013matched control study","volume":"26","author":"Liu","year":"2020","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10096-005-0004-z","article-title":"Treatment of severe acute respiratory syndrome","volume":"24","author":"Lai","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1469-0691.2004.00956.x","article-title":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients","volume":"10","author":"Soo","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"The RECOVERY Collaborative Group (2021). Dexamethasone in Hospitalized Patients with Covid-19. N. Engl. J. Med., 384, 693\u2013704.","DOI":"10.1056\/NEJMoa2021436"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Rajendran, K., Narayanasamy, K., Rangarajan, J., RathinamJeyalalitha, N.M., and Ramachandran, A. (2020). Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J. Med. Virol., in press.","DOI":"10.1002\/jmv.25961"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2013at arget for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1385\/CRIAI:29:3:207","article-title":"Anti-inflammatory effect of intravenous immunoglobulin mediated through modulation of complement activation","volume":"29","author":"Lutz","year":"2005","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nm836","article-title":"F(ab)\u20192-mediated neutralization of C3a and C5a anaphylatoxins: A novel effect or function of immunoglobulins","volume":"9","author":"Basta","year":"2003","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e01753-18","DOI":"10.1128\/mBio.01753-18","article-title":"Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis","volume":"9","author":"Gralinski","year":"2018","journal-title":"MBio"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-065X.1994.tb00854.x","article-title":"Anti-cytokine nature of natural human immunoglobulin: One possible mechanism of the clinical effect of intra venous immunoglobulin therapy","volume":"139","author":"Abe","year":"1994","journal-title":"Immunol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Basheer, M., Saad, E., Hagai, R., and Assy, N. (2021). Clinical Predictors of Mortality and Critical Illness in Patients with COVID-19 Pneumonia. Metabolites, 11.","DOI":"10.3390\/metabo11100679"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2020-218323","article-title":"Preliminary predictive criteria for COVID-19 cytokine storm","volume":"80","author":"Caricchio","year":"2021","journal-title":"Ann. Rheum. Dis."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/11\/11\/761\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:26:26Z","timestamp":1760167586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/11\/11\/761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["metabo11110761"],"URL":"https:\/\/doi.org\/10.3390\/metabo11110761","relation":{},"ISSN":["2218-1989"],"issn-type":[{"type":"electronic","value":"2218-1989"}],"subject":[],"published":{"date-parts":[[2021,11,5]]}}}